 double-blind trial periop fibrinolyt enhanc femoropoplit bypass patient rest pain acut peripher arteri thrombosi endogen fibrinolysi risk earli vascular graft thrombosi risk fibrinolyt shutdown major surgeri stanozolol endogen fibrinolysi attempt periop fibrinolyt shutdown graft patenc twenty-seven patient mg stanozolol oper week cours mg stanozolol placebo second day oper mbq autolog platelet scan graft follow day larg depot stanozolol signific effect plasminogen fibrinogen reduc euglobulin lysi time seventh day oper maximum benefit week platelet deposit studi placebo group progress increas platelet deposit day contrast stanozolol static pictur deposit chang statist signific patient earli graft thrombosi placebo group stanozolol group incomplet inhibit periop fibrinolyt shutdown much preoper cours maximum effect present crucial time present periop fibrinolyt enhanc practic proposit develop new safer potent agent